Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2013

View Archived Issues

Epizyme presents novel epigenetic-targeted, small-molecule anticancer agents

Researchers present updated results for CART-19 cell therapy

Exploration of a key mechanistic pathway of antiapoptotic signaling in multiple myeloma

German and U.S. researchers design novel transgenic rat model for Huntington's disease

Novel agents for heart failure presented by German researchers

Novo Nordisk discloses new ligands binding to IL-21

New labeled NMDA receptor ligands patented by group in The Netherlands

Merz Pharma presents novel NMDA glycine B receptor antagonists

Novel monoclonal antibodies divulged by Antitope

Theravance synthesizes new series of neprilysin inhibitors

TRU-016 receives orphan medicinal product designation in Europe for CLL

Probuphine obtains FDA priority review designation for opioid dependence

Synergy Pharmaceuticals reports data from phase IIb/III plecanatide trial

Phase II SGI-110 trial begins in hepatocellular carcinoma

Photocure receives payment for Lumacan from Salix Pharmaceuticals

AbbVie launched as independent biopharmaceutical company

Phase IIb data presented for vaccine against enterotoxigenic bacteria

Small-molecule FADK inhibitor demonstrates efficacy for brain cancers

Results from a first-in-human phase I trial presented for AR-42

Kareus Therapeutics announces commencement of phase I trial for Alzheimer's disease candidate

Nexavar meets primary endpoint in RAI-refractory differentiated thyroid cancer

Clinical hold lifted for OncoMed's demcizumab

FDA deems complete Merck & Co's resubmission of NDA for ezetimibe/atorvastatin tablets

Relypsa reaches agreement with FDA for phase III trial of patiromer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...